-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in Helius Medical Technologies, Inc. (NASDAQ:HSDT) Rises By 192.7%
Short Interest in Helius Medical Technologies, Inc. (NASDAQ:HSDT) Rises By 192.7%
Helius Medical Technologies, Inc. (NASDAQ:HSDT – Get Rating) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 173,600 shares, a growth of 192.7% from the July 15th total of 59,300 shares. Based on an average daily trading volume, of 2,350,000 shares, the short-interest ratio is presently 0.1 days.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of HSDT. Altium Capital Management LP bought a new position in shares of Helius Medical Technologies in the fourth quarter worth $254,000. Kepos Capital LP boosted its stake in Helius Medical Technologies by 296.4% in the fourth quarter. Kepos Capital LP now owns 100,304 shares of the company's stock valued at $521,000 after buying an additional 75,000 shares in the last quarter. Finally, AIGH Capital Management LLC acquired a new stake in Helius Medical Technologies in the fourth quarter valued at about $1,298,000. Institutional investors own 29.74% of the company's stock.
Get Helius Medical Technologies alerts:Helius Medical Technologies Stock Performance
Shares of NASDAQ HSDT opened at $0.51 on Thursday. Helius Medical Technologies has a 52 week low of $0.45 and a 52 week high of $15.68. The stock has a market capitalization of $1.94 million, a P/E ratio of -0.07 and a beta of 0.72. The stock's fifty day moving average is $1.33 and its 200 day moving average is $2.52.
Helius Medical Technologies (NASDAQ:HSDT – Get Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($1.15) EPS for the quarter. Helius Medical Technologies had a negative return on equity of 240.53% and a negative net margin of 3,043.95%. The company had revenue of $0.19 million during the quarter. During the same quarter in the prior year, the firm earned ($1.65) EPS. Equities research analysts forecast that Helius Medical Technologies will post -4.18 earnings per share for the current year.About Helius Medical Technologies
(Get Rating)
Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
Recommended Stories
- Get a free copy of the StockNews.com research report on Helius Medical Technologies (HSDT)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
Helius Medical Technologies, Inc. (NASDAQ:HSDT – Get Rating) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 173,600 shares, a growth of 192.7% from the July 15th total of 59,300 shares. Based on an average daily trading volume, of 2,350,000 shares, the short-interest ratio is presently 0.1 days.
和力士醫療技術公司(納斯達克:HSDT-GET評級)是7月份空頭股數大幅增長的接受者。截至7月31日,空頭股數共有173,600股,比7月15日的59,300股增長了192.7%。以日均成交量2,350,000股計算,目前短息比為0.1天。
Institutional Inflows and Outflows
機構資金流入和流出
A number of hedge funds have recently modified their holdings of HSDT. Altium Capital Management LP bought a new position in shares of Helius Medical Technologies in the fourth quarter worth $254,000. Kepos Capital LP boosted its stake in Helius Medical Technologies by 296.4% in the fourth quarter. Kepos Capital LP now owns 100,304 shares of the company's stock valued at $521,000 after buying an additional 75,000 shares in the last quarter. Finally, AIGH Capital Management LLC acquired a new stake in Helius Medical Technologies in the fourth quarter valued at about $1,298,000. Institutional investors own 29.74% of the company's stock.
多家對衝基金最近調整了對HSDT的持股。Altium Capital Management LP在第四季度購買了Helius Medical Technologies價值25.4萬美元的新頭寸。Kepos Capital LP在第四季度將其在Helius Medical Technologies的持股增加了296.4%。Kepos Capital LP現在擁有100,304股該公司股票,價值521,000美元,上個季度又購買了75,000股。最後,AIGH Capital Management LLC在第四季度收購了Helius Medical Technologies的新股份,價值約1,298,000美元。機構投資者持有該公司29.74%的股票。
Helius Medical Technologies Stock Performance
Helius醫療技術公司股票表現
Shares of NASDAQ HSDT opened at $0.51 on Thursday. Helius Medical Technologies has a 52 week low of $0.45 and a 52 week high of $15.68. The stock has a market capitalization of $1.94 million, a P/E ratio of -0.07 and a beta of 0.72. The stock's fifty day moving average is $1.33 and its 200 day moving average is $2.52.
週四,新浪納斯達克的股價開盤報0.51美元。Helius Medical Technologies的52周低點為0.45美元,52周高點為15.68美元。該股市值為194萬美元,市盈率為-0.07,貝塔係數為0.72。該股的50日移動均線切入位為1.33美元,200日移動均線切入位為2.52美元。
About Helius Medical Technologies
關於Helius醫療技術公司
(Get Rating)
(獲取評級)
Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
Helius醫療技術公司是一家神經技術公司,專注於開發、許可和獲取非侵入性技術,用於治療神經疾病或創傷引起的症狀。其產品便攜式神經調節刺激器(PONS)是一種非手術醫療設備,旨在用於短期治療因多發性硬化症症狀而導致的步態缺陷和因輕至中度創傷性腦損傷而導致的平衡障礙,以及與有監督的治療鍛鍊一起使用。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Helius Medical Technologies (HSDT)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
- 免費獲取StockNews.com關於Helius醫療技術(HSDT)的研究報告
- 大型和小型石油和天然氣類股盈利後反彈
- 連續十年上漲的兩隻道指股票
- Rite Aid會再次成為收購目標嗎?
- 投資石油股票的方式和原因
- 投資黃金股票的方式和原因
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《赫利烏斯醫療技術日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Helius醫療技術公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧